# Growth Hormone Axis research peptides: why the pulse is the whole story > Growth Hormone Axis research peptides — skyhighpeptides — An independent literature digest on Growth Hormone Axis research peptides — ipamorelin, CJC-1295, sermorelin and the CJC-1295 / ipamorelin combination — read through the one thing that separates them: the shape of the growth-hormone pulse. Cited, caveated, nothing for sale. **PULSATILITY · THE GROWTH HORMONE AXIS** Growth hormone does not trickle. It fires in bursts. Ipamorelin, CJC-1295, sermorelin and the CJC-1295 / ipamorelin pair are four different attempts to change the shape of those bursts — and the evidence behind each one is a different strength. ### [Ipamorelin](/ipamorelin) ![Ipamorelin research illustration](images/ipamorelin.webp) The sharp, short answer. A five-residue ghrelin-receptor agonist that produces a single discrete growth-hormone pulse peaking around 40 minutes after dosing, without dragging cortisol and prolactin up with it [4][6]. Its one published Phase 2 trial in humans missed its primary endpoint [3]. ### [CJC-1295](/cjc-1295) ![CJC-1295 research illustration](images/cjc-1295.webp) The long answer. A GHRH analogue engineered to latch onto serum albumin, stretching its half-life to 5.8–8.1 days and holding growth hormone and IGF-1 up for over a week [11]. The interesting part: pulse frequency and amplitude were unchanged underneath that raised baseline [12]. ### [Sermorelin](/sermorelin) ![Sermorelin research illustration](images/sermorelin.webp) The unmodified answer. The natural GHRH signal cut down to its shortest fully active fragment — no half-life engineering, feedback braking left intact [15]. It is also the only compound here with a real regulatory history and a controlled pediatric growth outcome [16]. ### [CJC-1295 / Ipamorelin](/cjc1295-ipamorelin) ![CJC-1295 / Ipamorelin research illustration](images/cjc1295-ipamorelin.webp) The both-at-once answer. Two receptors, two second messengers; co-activating them in transfected cells roughly doubled the cAMP response versus GHRH-receptor activation alone [20]. The fixed blend itself has never been through a controlled human trial. ## The short version The body does not release growth hormone in a steady stream. It releases it in **bursts** — short spikes, largest during deep sleep, separated by long quiet stretches when the blood level sits close to zero. Endocrinologists call this *pulsatile* secretion, and it is not a quirk of plumbing. Tissues respond differently to a sharp spike than they do to the same total amount of hormone spread flat across a day. That one fact organises this whole site. Injecting growth hormone itself overrides the pattern: the level goes up and stays up. The four compounds covered here take a different route. Rather than supplying the hormone, they lean on the **pituitary** — the small gland at the base of the brain that makes it — and ask it to fire. Because the gland is still in charge, the body's own braking system is still attached. Each of the four leans on the pituitary differently, and the published evidence for each is a different strength. What follows is what has actually been measured, with every number traced to its source. ## Why the pulse, and not a steady drip Growth-hormone release is governed by a push and a pull. Growth-hormone-releasing hormone (GHRH), made in the hypothalamus, pushes: it binds a receptor on pituitary somatotrophs, raises intracellular cAMP through a Gs-coupled pathway, and drives both synthesis and release. Somatostatin pulls the other way. The alternation of those two signals, layered over a third input from the ghrelin receptor, is what carves a smooth hormonal supply into discrete beats. A 2025 *Nature Reviews Endocrinology* review of GHRH and its analogues sets out that receptor biology and the design logic behind long-acting analogues in detail [8]. Two receptors on the same cell matter here, because the compounds on this site split neatly between them. GHRH analogues — sermorelin and CJC-1295 — work the GHRH receptor and its cAMP pathway. Ghrelin-receptor agonists — ipamorelin — work GHS-R1a and a calcium-linked pathway instead. They are not redundant. When both receptors were co-activated in transfected cells, the cAMP response was roughly twice that of GHRH-receptor activation alone, which is the receptor-level case for combining them [20]. The clinical argument that gets built on top of this is that a secretagogue is *more physiologic* than exogenous growth hormone, because pituitary feedback through somatostatin and IGF-1 stays intact and the natural pulse pattern is preserved [15]. That argument is worth stating plainly and then immediately qualifying: it is largely a mechanistic and editorial case, and the source making it is an editorial, not a trial. The strongest direct measurement in its favour comes from a study of CJC-1295 in healthy young men, where the frequency and magnitude of pulsatile secretion were unaltered even while basal growth hormone sat roughly 7.5-fold above starting values a week after a single dose [12]. That is one study, in one population, with a surrogate endpoint — hormone levels, not health outcomes. ## Four answers to one question Ask how to raise growth hormone without flattening the pulse and these four compounds give four genuinely different answers. **Ipamorelin answers with amplitude.** It is a five-amino-acid ghrelin-receptor agonist with a terminal half-life of roughly two hours; in healthy male volunteers the growth-hormone response arrived as a single discrete pulse peaking about 40 minutes after dosing [4]. Its founding characterisation showed potent release in rat pituitary cells, rats and conscious swine without raising ACTH or cortisol above the level seen with GHRH, even at doses more than 200-fold above its growth-hormone ED50 [6]. A short, clean, isolated beat. **CJC-1295 answers with duration.** Four protease-resistant substitutions plus a linker that bonds covalently to serum albumin give it an estimated half-life of 5.8–8.1 days; single subcutaneous doses raised mean plasma growth hormone 2- to 10-fold for six days or more and IGF-1 1.5- to 3-fold for 9–11 days [11]. The pulse itself, remarkably, survived underneath that [12]. This is a raised floor, not a bigger beat. **Sermorelin answers by not answering.** It is GHRH(1–29), the shortest fragment of the natural hormone that keeps full activity — no albumin trick, no half-life engineering. The claim is that leaving the signal alone leaves the feedback loop alone [15]. Its best controlled human outcome data is pediatric: once-daily subcutaneous dosing in prepubertal growth-hormone-deficient children raised first-year height velocity from about 4.1 cm/year to roughly 7–8 cm/year without excessive IGF-1 generation [16]. **The combination answers with both.** Pairing the GHRH arm with the ghrelin arm is an attempt to keep CJC-1295's raised background *and* ipamorelin's sharp pulse. The receptor-level rationale is solid [20]. The blend itself has never been tested as a fixed combination in a controlled human trial, and its two halves run on wildly mismatched clocks — days versus hours. ## What "research peptide" means on this site A research peptide is a short chain of amino acids sold and handled for laboratory work rather than for treating people. Three of the four compounds here have never been approved as a medicine by any regulator, anywhere. That is a fact about their legal status, and it is also a fact about their evidence base: no approval means no Phase 3 programme, and no Phase 3 programme means no long-term human safety database. Ipamorelin's history makes the point bluntly. It was investigated, it reached a Phase 2 randomised controlled trial in 114 adults after bowel resection, and it **missed** its primary endpoint — median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, which did not reach significance [3]. Lack of approval here reflects a development programme that did not deliver, not merely one that stalled. Sermorelin is the exception that needs stating precisely: it was genuinely FDA-approved, as a branded sermorelin acetate product for pediatric growth-hormone deficiency, and it was withdrawn from the US market in 2008 for commercial reasons rather than because of a safety or efficacy problem. It is not currently a marketed FDA-approved drug, and it is not a withdrawn-for-harm drug either. Both mistakes are common online; the [sermorelin page](/sermorelin) sets the record out in full. One more framing note, because it governs how everything on this site should be read. A great deal of the evidence for these compounds is measured in **surrogate endpoints** — how much growth hormone or IGF-1 went up — rather than in outcomes anyone would notice. Raising IGF-1 is not the same as getting stronger, leaner, sharper or healthier, and the pages here flag the difference every time it matters. All four compounds are also prohibited in sport at all times under WADA category S2, and detection methods for them are established. --- A literature digest on the growth-hormone axis, written to keep the pulse — and the evidence behind it — in proportion; not a clinic, not a pharmacy, and not medical advice.